Lantus Solostar

Lantus Solostar belongs to the group of antidiabetic immunobiological insulin preparations, analogues of human insulin, designed to reduce blood sugar levels with its prolonged action.

This drug has a hypoglycemic effect due to the fact that glucose is more actively absorbed by the tissues of the body after the binding released insulin into the blood with the receptors of muscle cells and lipids. At the same time, the secretion of glucose by liver cells is inhibited.

After subcutaneous injection, the acid solution of Lantus Solostar is neutralized, which leads to the appearance of microprecipitates, from which a small amount of insulin glargine is constantly released, providing a smooth (without peaks) and predictable concentration-time profile, as well as a longer drug effects.

Insulin glargine is metabolized to 2 active metabolites - M1 and M2.

Insulin receptor binding:

The results of in vitro studies show that the affinity of insulin glargine and its metabolites M1 and M2 to the human insulin receptor is similar to the affinity of human insulin.

IGF-1 receptor binding (insulin-like growth factor 1):

The affinity of insulin glargine for the IFR-1 receptor is about 5-8 times higher than the affinity of human insulin (but about 70-80 times lower than the affinity of IFN-1 for this receptor), while the metabolites M1 and M2 bind to the IGF-1 receptor with affinity, slightly lower than the affinity of human insulin.

Lantus Solostar contains insulin glargine - an analogue of long-acting insulin. The drug is administered once daily at any time of day, but every time at one and the same time.

Dosage regimen of Lantus Solostar (dose and time of administration) should be selected individually. Patients with Type II diabetes mellitus can also be co-administered with oral antidiabetic medicines. The strength of this medicinal product is expressed in units. These units apply exclusively to the Lantus Solostar drug and are different from the IU or units that express the strength of other insulin analogues.

Always follow your doctor`s instructions when using Resihance (Regorafenib) to get the safest and most effective results from treatment.

As a rule, the most common adverse reaction is hypoglycemia (seen very often) that occurs during insulin therapy. It occurs when the dose of insulin injected far exceeds the need for it.

The safety and efficacy of Lantus Solostar Insulin have been proven when used for adolescents and children over the age of 2 years. The use of Lantus Solostar in children under the age of 2 years has not been studied.

Older patients (over 65 years of age)

In advanced age patients, progressive deterioration of the kidney function can lead to a permanent reduction in insulin requirements.